Most recent Study on Industrial Growth of Global Pitavastatin Market 2020-2027. A point by point study gathered to offer Latest knowledge about intense highlights of the Pitavastatin market. The report contains distinctive market expectations identified with CAGR, income, production, Consumption, market size, gross margin, cost and other considerable elements.

While highlighting the key driving…

Lupin Ltd, Patent, Pitavastatin, WO2014203045

Lupin Ltd, Patent, Pitavastatin, WO2014203045 A NOVEL, GREEN AND COST EFFECTIVE PROCESS FOR SYNTHESIS OF TERT-BUTYL (3R,5S)-6-OXO-3,5-DIHYDROXY-3,5-O-ISOPROPYLIDENE-HEXANOATE ROY, Bhairabnath; (IN). SINGH, Girij, Pal; (IN). LATHI, Piyush, Suresh; (IN). AGRAWAL, Manoj, Kunjabihari; (IN). MITRA, Rangan; (IN). TRIVEDI, Anurag; (IN). PISE, Vijay, Sadashiv; (IN). RUPANWAR, Manoj; (IN) The present…

Lupin Ltd, New patent, Pitavastatin, WO 2016005919

Formula (1) Lupin Ltd, New patent, Pitavastatin, WO 2016005919 MANE, Narendra, Dattatray; (IN). NEHATE, Sagar, Purushottam; (IN). GODBOLE, Himanshu, Madhav; (IN). SINGH, Girij, Pal; (IN) The present invention is directed to polymorphic forms of Pitavastatin sodium and processes for preparation of the same Novel crystalline polymorphic forms (I and II) and an amorphous form of pitavastatin, useful…

Medicinal Chemistry International: PITAVASTATIN

Pitavastatin might prevent endothelial dysfunction caused by postprandial hypertriglyceridemia within 2 weeks of therapy in obese subjects. Obesity is a well-established risk factor for the development and progression of coronary heart disease. Moreover, endothelial dysfunction is an early event in atherosclerosis and is known to be associated with postprandial hypertriglyceridemia.

Amplify’d from www.ncbi.nlm.nih.gov

Heart Vessels. 2010 Dec 4. [Epub ahead of print]

Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects.

Nagashima H, Endo M.

Source

Department of Cardiology, Tokyo Heart Center, Osaki Hospital, Tokyo, Japan, [email protected].

Abstract

Obesity is a well-established risk factor for the development and progression of coronary heart disease. Moreover, endothelial dysfunction is an early event in atherosclerosis and is known to be associated with postprandial hypertriglyceridemia. The purpose of this study was to determine whether a statin might have an effect on postprandial hypertriglyceridemia, and thereby on endothelial function in obese subjects. Twenty-four obese male subjects were recruited for this study. They were randomly assigned to receive pitavastatin (2 mg/day) or placebo for 2 weeks. The oral fat loading test using OFTT cream was performed pre- and post-treatment, in which the lipid profile and flow-mediated dilation (FMD) were assessed before and 4 h after an oral fat load. In the oral fat loading test conducted pretreatment, the oral fat load induced a marked increase of the serum triglyceride (TG) level and decrease in FMD in the pitavastatin and placebo group. In the test conducted post-treatment, the increase in postprandial TG was attenuated (+183 vs. +81 mg/dL, P < 0.001) and decrease in postprandial FMD was completely abolished (-1.1 vs. +0.1%, P < 0.01) by pitavastatin treatment. Moreover, there was a good correlation between the change in postprandial TG and the change in postprandial FMD after the 2 weeks of treatment (r = -0.737, P < 0.001). Pitavastatin might prevent endothelial dysfunction caused by postprandial hypertriglyceridemia within 2 weeks of therapy in obese subjects.

Read more at www.ncbi.nlm.nih.gov